Antifungals and resistance

February 1996
AIDS Patient Care & STDs;Feb1996, Vol. 10 Issue 1, p54
Academic Journal
Presents information from a research done on fungi and its resistance to antifungal drugs. Where most of the resistance have taken place; Impact on HIV-infected persons.


Related Articles

  • New antifungal active against opportunistic infections.  // AIDS Patient Care & STDs;Feb1997, Vol. 11 Issue 1, p37 

    Reports on Premidicin, an antifungal agent from Bristol-Myers. Effectivity of the drug against asperigillosis, candida and cryptococcus.

  • Itraconazole Oral Solution as Prophylaxis for Fungal Infections in Neutropenic Patients with Hematologic Malignancies: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Menichetti, Francesco; Del Favero, Albano; Martino, Piero; Bucaneve, Giampaolo; Micozzi, Alessandra; Girmenia, Corrado; Barbabietola, Giuliana; Pagano, Livio; Leoni, Pietro; Specchia, Giorgina; Caiozzo, Alessandro; Raimondi, Roberto; Mandelli, Franco // Clinical Infectious Diseases;2/1/1999, Vol. 28 Issue 2, p250 

    To evaluate the efficacy and safety of itraconazole oral solution for preventing fungal infections, a randomized, placebo-controlled, double-blind, multicenter trial was conducted: 405 neutropenic patients with hematologic malignancies were randomly assigned to receive either itraconazole, 2.5...

  • Reply to Dr. Chandrasekar (Clin Infect Dis 2001; 32: 320-1) and Drs. Marr and Boeckh (Clin... Rex, John H.; Walsh, Thomas J.; Sobel, Jack D.; Filler, Scott G.; Pappas, Peter G.; Dismukes, William E.; Edwards, John E. // Clinical Infectious Diseases;2/1/2001, Vol. 32 Issue 3, p518 

    Responds to a critique of the authors' research on the use of fluconazole for the treatment of neutropenia. Use of the treatment in selected circumstances; Efficacy of the treatment; Timing of initiation of antifungal therapy.

  • A Randomized Double-Blind Study of Caspofungin versus Amphotericin for the Treatment of Candidal Esophagitis. Villianueva, Alvaro; Arathoon, Eduardo G.; Gotuzzo, Eduardo; Berman, Rayanne S.; DiNubile, Mark J.; Sable, Carole A. // Clinical Infectious Diseases;11/1/2001, Vol. 33 Issue 9, p1529 

    Provides information on a study which assessed the efficacy, safety and tolerability of caspofungin, an antifungal drug, relative to amphotericin B in adults with endoscopically documented symptomatic Candida esophagitis. Methodology; Characteristics of the study population; Findings of...

  • Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia. Yu, Donghui T; Seger, Diane L; Peterson, Josh F; Kumar, Ritesh N; Bates, David W // BMC Infectious Diseases;2006, Vol. 6 Issue 1, p173 

    Background: Several clinical trials have demonstrated the efficacy of fluconazole as empiric antifungal therapy in cancer patients with fever and neutropenia. Our objective was to assess the frequency and resource utilization associated with treatment failure in cancer patients given empiric...

  • Sources Influencing Patients in Their HIV Medication Decisions. Meredith, Karen L.; Jeffe, Donna B.; Mundy, Linda M.; Fraser, Victoria J. // Health Education & Behavior;Feb2001, Vol. 28 Issue 1, p40 

    The authors surveyed 202 patients (54.5% male; 62.4% African American) enrolled at St. Louis HIV clinics to identify the importance of various sources of influence in their HIV medication decisions. Physicians were the most important source for 122 (60.4%) respondents, whereas prayer was most...

  • Flood damage. Gallagher, John // Advocate;9/7/93, Issue 637, p24 

    Examines the impact of the flooding in the Midwest on the medical care of HIV-positive people. Magnitude of the disaster; Impact on AIDS organizations; Fundraising efforts.

  • Learn and live: Physicians' HIV experience. Pinkowish, Mary Desmond // Patient Care;5/15/1996, Vol. 30 Issue 9, p18 

    Focuses on the experience of physicians in treating HIV-infected patients as a survival factor in HIV disease. Study of patients with HIV in the Group Health Cooperative of Puget Sound, Washington; Median survival as based on physician experience; Prescription of prophylaxis prior to developing...

  • Controlled Trials of Amphotericin B Lipid Complex and Other Lipid-Associated Formulations. Winston, Drew J.; Schiller, Gary J. // Clinical Infectious Diseases;1/1/2000, Vol. 30 Issue 1, p236 

    Comments on an article on an uncontrolled study of the antifungal infection drug amphotericin B lipid complex (AB-LC) published in a 1998 issue of the 'Clinical Infectious Diseases' journal. Details of two trials on AB-LC not mentioned by the article; Necessity for doctors to consider...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics